Category Archives: General
การภาคสนาม มีความไวกว่าตัวเลือกในปัจจุบั นถึง 80,000 ครั้ง
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) — ในขณะที่ชุมชนโลกมารวมตัวกั
บริษัท Meridian Bioscience, Inc. ใน Cincinnati, Ohio (NASDAQ:VIVO) ได้พัฒนา illumigene® Malaria ขึ้นซึ่งเป็นการทดสอบที่ใช้
“illumigene Malaria มีศักยภาพในการเปลี่
illumigene Malaria ได้รับรางวัลที่หนึ่งสำหรับนวั
เมื่อรวบรวมรายงานแล้ว เกือบร้อยละ 43 ของกรณีโรคมาลาเรียที่จดทะเบี
ความพร้อมใช้งานของ illumigene Malaria ซึ่งเป็นการทดสอบที่ใช้ได้ในห้
illumigene Malaria จะมีจัดจำหน่ายในยุโรป ตะวันออกกลาง และแอฟริกาโดยบริษัท Meridian Bioscience Europe และในตลาดต่างประเทศเพิ่มเติ
1 – ข่าวประชาสัมพันธ์ของ Meridian “การทดสอบมาเลเรียใหม่ illumigene Malaria ได้กำหนดมาตรฐานใหม่ในการวินิ
2 – องค์การอนามัยโลก: 10 ข้อเท็จจริงเกี่ยวกับโรคมาลาเรี
3 – เช่นเดียวกับข้อ 2
4 – เช่นเดียวกับข้อ 2
5 – เช่นเดียวกับข้อ 2
6 – องค์การอนามัยโลก, กลยุทธ์
เกี่ยวกับบริษัท Meridian Bioscience, illumigene Malaria และเทคโนโลยี LAMP
- illumigene Malaria เป็นการตรวจวินิจฉัยโรคมาลาเรี
ยที่ได้รับการพัฒนาโดยบริษัท Meridian Bioscience โดยเป็นการทดสอบระดับโมเลกุลที่ ใช้เทคโนโลยี Isothermal Loop-Mediate Amplification (LAMP) เพื่อขยาย DNA และตรวจจับการปรากฏตัวของปรสิ ตมาลาเรีย
- LAMP (Loop Mediated Isothermal Amplification) คือเทคโนโลยีการตรวจจับระดั
บโมเลกุลที่กำหนดเป้าหมาย DNA และใช้สารรีเอเจนต์ที่ตรวจวั ดได้และมีอยู่ในตัว แตกต่างจากการทดสอบ PCR ในปัจจุบัน LAMP ไม่จำเป็นต้องมีรอบอุณหภูมิ แต่สามารถทำการอบ ตรวจจับ และรายงานที่อุณหภูมิเดียวเพื่ อให้ได้ผลลัพธ์ที่รวดเร็วขึ้น ชุดทดสอบ illumigene สามารถเก็บไว้ภายใต้ สภาพแวดล้อมที่มีอยู่ ในขณะที่วิธีการโมเลกุลในปัจจุ บันจำเป็นต้องเก็บในความเย็น
- เทคโนโลยี illumigene ไม่ยุ่งยาก ถูกต้อง และใช้งานได้ง่าย ซึ่งหมายความว่าไม่จำเป็นต้องมี
ผู้เชี่ยวชาญด้านเทคนิคเพื่ อทำการทดสอบ จะได้ผลลัพธ์ภายในเวลาไม่ถึงหนึ่ งชั่วโมง
- การทดสอบ illumigene ซึ่งใช้เทคโนโลยี LAMP เป็นพื้นฐานพร้อมสำหรับวินิจฉั
ยโรคติดเชื้อ ได้แก่ C. difficile โรคไอกรน และ ไวรัสเริม ซึ่งพิสูจน์แล้วว่ามีความแม่ นยำสูง
- การทดสอบ illumigene ได้รับการอนุมัติ
และสามารถใช้ในโรคอื่นๆ มานานกว่า 5 ปีแล้ว
- ข้อดีของ illumigene Malaria ได้รวบรวมไว้ที่ www.molecularendsmalaria.com.
เกี่ยวกับบริษัท Meridian Bioscience, Inc
กลงทุน กรุณาติดต่อ: 513-271-3700 John A. Kraeutler ประธานเจ้าหน้าที่บริหาร สำหรับข้อซักถามอื่นๆ กรุณาติดต่อ: 513-403-7222 Joe Shields
Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) — As the global community gathers for World Malaria Day to celebrate successes and plot strategy to eliminate the disease from the face of the earth, a new ray of hope is emerging from a surprising place: the testing side of the equation.
Meridian Bioscience, Inc. of Cincinnati, Ohio (NASDAQ:VIVO) has developed illumigene® Malaria, a molecular-based, field laboratory-deployed test for malaria that is up to 80,000 times more sensitive at detecting the malaria parasite than current testing options. The test was developed by Meridian with the technical assistance of the Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal.
“illumigene Malaria has the potential to change current practices. Faster and more accurate diagnosis is vital in the fight against malaria,” said Professor Daouda Ndiaye, Department of Parasitology-Mycology, Cheikh Anta Diop University. “Earlier diagnosis enables the correct treatment to be prescribed, which leads to better clinical outcomes for the person with malaria and keeps malaria treatments for the right people. And because detecting the malaria parasite in people with a low parasite count has proven difficult, a robust, sensitive and field laboratory-deployable diagnostic tool is needed to track the malaria reservoir in pre-elimination regions. illumigene Malaria shows this capacity.”
illumigene Malaria was awarded first place for innovation in emergency treatment and point-of-care testing at the prestigious Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference in Paris, and is CE marked for sale in Europe.
Despite a 60% decline in malaria deaths since 2000 due to better prevention and increased control measures, malaria is still one of the top three killers of children worldwide, claiming one life every minute of every day. (1) According to the latest data from the World Health Organization, nearly half of the world’s population is at risk of malaria (2). In 2015, there were roughly 212 million malaria cases and an estimated 429,000 malaria deaths (3). Also that year, Sub-Saharan Africa was home to 90% of malaria cases and 92% of malaria deaths (4). More than two-thirds (70%) of all malaria deaths occur in children under the age of five (5).
While malaria is preventable and treatable (6), proper diagnosis is critical. Molecular testing has proven to be more effective than current options in detecting the malaria parasite at very low levels, known as “loads.” Identifying low-load individuals has the dual benefit of ensuring they receive treatment and preventing the spread of the disease to others.
“People can be carriers of malaria without showing any symptoms, and detecting these asymptomatic individuals can be challenging,” said Slava Elagin, Executive Vice President, Research & Development at Meridian Bioscience. “If testing doesn’t identify them, eliminating malaria is impossible because these individuals can spread the disease to others.”
That scenario is playing out in the fact that malaria is no longer only a disease of sub-Saharan Africa and southern Asia. Increasing numbers of people emigrating from countries where malaria is endemic have resulted in a higher incidence in Europe and the Middle East. The proportion of imported malaria cases has increased during the last few years from 14% to 86% in more recent studies. On pooling the reports, nearly 43% of malaria cases registered in key European centers occurred in non-nationals. The rates of malaria are much higher in settled immigrants who travel to visit friends and relatives in their country of origin. They can account for up to 70% of the cases in several reports and this increase highlights the need for better diagnostic tools in both non-endemic and endemic countries.
While not a new concept, molecular testing has traditionally been a complex process requiring fully-equipped laboratories and highly trained testing personnel. The breakthrough of illumigene Malaria by Meridian Bioscience is that it can be deployed in the field laboratory, where malarial infection is the highest and low load detection most challenging to diagnose and treat. illumigene Malaria is user-friendly, doesn’t require special training or capital investment, yields results in under one hour and the testing materials can be stored at room temperature.
“This is a major step forward in the fight to bring better care to those infected with malaria and to stop its spread,” said John A. Kraeutler, Chief Executive Officer and Chairman of the Board of Meridian Bioscience.
The availability of the field laboratory-deployable and user-friendly, illumigene Malaria, will enhance rather than replace existing testing protocols. It will join rapid diagnostic tests (RDTs) and microscopy to create a web of detection protocols that will help direct treatment where it is needed most.
“Malaria is a devastating disease and we are proud to work with all the talented and dedicated individuals around the world in the fight to eliminate it,” said Kraeutler.
illumigene Malaria will be distributed in the European, Middle Eastern and African regions by Meridian Bioscience Europe and in additional international markets by the Company’s global distribution network. It is the tenth assay now available on our illumigene platform that is in use in nearly 1,500 institutions around the world.
1 – Meridian news release, “New Malaria Test, illumigene Malaria, Sets a New Gold Standard for Diagnosis”, 1.26.16
2 – World Health Organization: 10 facts on malaria (http://www.who.int/features/
3 – ibid
4 – ibid
5 – ibid
6 – The World Health Organization, Global Technical Strategy for Malaria: 2016-2030
About Meridian Bioscience, illumigene Malaria & LAMP Technology
- illumigene Malaria is a diagnostic test for malaria developed by Meridian Bioscience. It is a molecular test that uses Loop-Mediated Isothermal Amplification (LAMP) technology to amplify DNA and detect the presence of the Malaria parasite.
- LAMP (Loop Mediated Isothermal Amplification) is Molecular detection technology which targets DNA and uses premeasured and self-contained reagents. Unlike current PCR testing, it does not require temperature cycling. LAMP incubates, detects and reports at a single temperature, allowing for faster results. illumigene testing kits can be stored under ambient conditions, while current molecular methods require cold storage.
- illumigene technology is simple, accurate and easy to use which means that no specialist technical expertise is needed to perform the test. Results are available in under an hour.
- LAMP-based illumigene tests are already used to diagnose infectious diseases including C. difficile, whooping cough and Herpes Simplex Virus, where they have proved highly accurate.
- illumigene tests have been approved and used in other diseases for over 5 years.
- The benefits of illumigene Malaria are highlighted on the microsite: www.molecularendsmalaria.com.
About Meridian Bioscience, Inc
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
For Investor Relations, contact: 513-271-3700 John A. Kraeutler, Chief Executive Officer For all other inquiries, contact: 513-403-7222 Joe Shields
- Quantum Global Research Lab launches Africa Investment Index
- Morocco, Egypt, South Africa and Zambia amongst top five investment destinations
- Top five investment destinations attracted a combined net FDI of $13.6bn
LONDON, April 19, 2017 (GLOBE NEWSWIRE) — Botswana is the most attractive economy for investments flowing into the African continent, according to the latest Africa Investment Index 2016 (http://APO.af/sUtRNQ) by Quantum Global’s (www.QuantumGlobalGroup.com) independent research arm, Quantum Global Research Lab.
Multimedia content can be accessed here: http://APO.af/ZihCNl.
According to the Index, Botswana, scores highly based on a range of factors that include improved credit rating, current account ratio, import cover and ease of doing business.
Commenting on the Index, Prof Mthuli Ncube, Head of Quantum Global Research Lab stated: “Despite considerable external challenges and the fall in oil prices, many of the African nations are demonstrating an increased willingness to achieve sustainable growth by diversifying their economies and introducing favourable policies to attract inward investments. Botswana is a case in example – its strategic location, skilled workforce and a politically stable environment have attracted the attention of international investors leading to a significant influx of FDI.”
According to the report, the top five African investment destinations attracted an overall FDI of $13.6bn. Morocco was ranked second on the Index based on its increasing solid economic growth, strategic geographic positioning, increased foreign direct investment, import cover ratio, and an overall favourable business environment. Egypt was ranked third due to an increased foreign direct investment and real interest rates, and a growing urban population. The fourth country on the list, South Africa, scored well on the growth factor of GDP, ease of doing business in the country and significant population. Whilst Zambia, was the fifth country on the list due to its significant domestic investment and access money supply.
Table: Top 10 and Bottom 10 countries (view the multimedia content section: http://APO.af/1LpDdA).
Mthuli further commented: “With a population of over one billion people and rapidly growing middle class, Africa clearly offers significant opportunities to invest in the continent’s non-commodities sectors such as financial services, construction and manufacturing amongst others. However, structural reforms and greater private sector involvement are crucial to unlocking Africa’s true potential.”
Distributed by APO on behalf of Quantum Global Group.
To the editor:
Construction of the Index:
The AII is constructed from macroeconomic and financial indicators and the World Bank Group’s Ease of Doing Business Indicators (DBI). The DBI ranks countries in terms of a regulatory environment conducive to business operation. The AII focuses on 6 pillars or factors from a wider range of investment indicators, which include the share of domestic investment in GDP, the share of Africa’s total FDI net inflow, GDP growth rate forecast, population augmented GDP growth factor, real interest rate, the difference of broad money growth to the GDP growth rates, inflation differential, credit rating, import cover, the share of the country’s external debt in its GNI, current account ratio, ease of doing business and the country’s population size (Figure 1). The AII indicators are based on secondary data collected from World Bank Development Indicators, IMF World Economic Outlook, UNCTAD Data Centre and own estimates.
The AII is a combination of individual indicator’s rank into a single numerical ranking. It averages the country’s macroeconomic and financial indicators rankings on the six different factors. Each indicator, and hence factors, receives an equal weight. Their rank score is then averaged to produce the total average score which is consequently ranked from 1 to 54. The lower the value of the ranking, the better the implied business investment climate.
To produce an index score that captures medium-term changing aspects, individual country’s ranking is scaled relative to a benchmark or reference value (i.e., the past 3-year rolling average ranking). See Table 1A. In addition to the intended measurement, this approach enables us to avoid periods of structural changes (which may compromise the index) that may be present in a longer time span, whether we consider a change from a reference average value or a historical reference period.
About Quantum Global:
Quantum Global (www.QuantumGlobalGroup.com) is an international group of companies active in the areas of private equity investments, investment management as well as macroeconomic research and econometric modelling. Quantum Global’s private equity arm manages a family of funds targeting direct investments in Africa in the sectors of Agriculture, Healthcare, Hotels, Infrastructure, Mining and Timber – as well as a sector agnostic Structured Equity fund. Our team combines a solid track record and proven expertise to identify and execute unique investment opportunities with focus on Africa.
Enquiries: Linda Martin + 41 41 560 2900 media@QuantumGlobalGroup.com
การศึกษาวิจัยใหม่ที่ตีพิมพ์ในวารสาร PLOS ONE ซึ่งเป็นการศึกษาทางวิทยาศาสตร์ขั้นสูงเกี่ยวกับ VTS-270 เพื่อรักษาโรคนีมานน์-พิค ชนิดซี 1
ROCKVILLE, Maryland, April 19, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP) บริษัทชีวเภสัชภัณฑ์ระดับโลก วันนี้ได้ประกาศการตีพิมพ์งานวิ
NPC-1 เป็นโรคที่พบไม่บ่อย มีการลุกลาม เป็นโรคทางพันธุกรรมและมีอั
ในการศึกษาวิจัยนี้ นักวิจัยได้แสดงให้เห็นว่า VTS-270 มีระดับความสอดคล้องในปฏิกิริ
เกี่ยวกับ Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. มุ่งเน้นในการพัฒนาและทำธุรกิ
โลโก้และสโลแกนของ Sucampo, Science of Innovation เป็นเครื่องหมายการค้าจดทะเบี
ติดตามเราที่ Twitter (@Sucampo_Pharma) ติดตามเราที่ LinkedIn (Sucampo Pharmaceuticals)
ติดต่อเรา: Sucampo Pharmaceuticals, Inc. Silvia Taylor รองกรรมการผู้จัดการอาวุโส ฝ่ายนักลงทุนสัมพันธ์และองค์
กรสัมพันธ์ 1-240-223-3718 email@example.com
Expansion of the WFH Humanitarian Aid Program Demonstrates Significant Results Due to the Contribution of 500 Million IUs Donation of Bioverativ and Sobi
MONTREAL, April 17, 2017 (GLOBE NEWSWIRE) — The paradigm shift that has occurred through the expansion of the WFH Humanitarian Aid Program has resulted in significant improvements in the lives of those living with bleeding disorders in developing countries throughout the world. This is as a direct result of the significant level of donations committed by Bioverativ and Sobi, 500 million international units (IU) of clotting factor concentrates (CFC) treatment products, over 5 years, along with their substantial financial support for the operational needs of this program.
The WFH Humanitarian Aid Program was established in 1996, with more than 462 million IUs of treatment products channelled since it began, to more than 100,000 people in need, in 90 countries. Prior to the expansion of this program, donations were sporadic and existing commitments allowed for only emergency relief in dire situations.
In 2014, 21 million IUs of treatment products were channelled through the WFH Humanitarian Aid Program. In 2016, the donations rose to 122 million IUs, with this level per year to remain consistent until at least 2020. This translates into a rise from 2,119 patients treated in 2014 to over 12,300 patients reported just in 2016.The projected number of patients to be treated each year with this donation from Bioverativ and Sobi is expected to be approximately 21,000.
“The WFH Humanitarian Aid Program has transformed, over the past two years, into one of the most effective global programs in addressing the significant treatment gaps that occur for those living without much needed care,” said Alain Weill, WFH President.
The cost of treatment is prohibitively expensive for the majority of those affected with a bleeding disorder. Due to the limited access to diagnosis and treatment in many developing countries, people with severe hemophilia in these areas often do not survive to adulthood.
The direct impact of this sustainable and predictable model demonstrates significant transformation within the global bleeding disorders community. Life and limb-saving surgeries have climbed from 21 in 2014, to a total of 795 in 2016. As of the end of March 2017, this number has risen to over 1000. The immediate impact on quality of life is evident for those living with debilitating effects of joint damage, or having to put off other necessary surgeries due to the lack of treatment products.
Moreover, prior to the expansion of this program, people with bleeding disorders in developing countries had no opportunity to be put on a prophylaxis treatment regime, the standard of care in most of the developed world. In 2016, 852 people were placed on prophylaxis, with an additional 129 added onto this regime so far in 2017.
Last year, the WFH and WFH USA called for action to address the need for Treatment for All through the WFH Humanitarian Aid Program. This meant not only the commitment of donated treatment products, but also the financial support to allow for this program to become operationally successful.
In addition to these donations, the WFH Humanitarian Aid Program provides a wide range of integrated clinical training programs to ensure the local infrastructure and medical expertise are available to optimize use of donated products.
“The WFH Humanitarian Aid Program is an integral part of addressing the major gaps that exist for the majority of people in the world living with a bleeding disorder,” said Mark Skinner, WFH USA President.
The ongoing support of Bioverativ and Sobi to this program demonstrates strong leadership in providing certainty to those most in need. We continue to work with all our global partners to come together to further strengthen the success of the WFH Humanitarian Aid Program.
About the World Federation of Hemophilia
For over 50 years, the World Federation of Hemophilia (WFH), an international not-for-profit organization, has worked to improve the lives of people with hemophilia and other inherited bleeding disorders. Established in 1963, it is a global network of patient organizations in 134 countries and has official recognition from the World Health Organization. Visit WFH online at www.wfh.org.
WFH USA advances the global mission of the World Federation of Hemophilia in the United States.
About the WFH Humanitarian Aid Program
For many developing countries, product donations are often the only source of treatment product for patients with hemophilia and other bleeding disorders. The WFH receives requests, many urgent in nature, from WFH national member organizations (NMOs) and from recognized hemophilia treatment centers (HTCs) around the world. An increasing number of collaborators within the global bleeding disorders community have accepted the challenge of providing a sustainable and predictable supply of donated products. Through the donation by Bioverativ and Sobi to the WFH Humanitarian Aid Program of up to 500 million IUs within five years, the Grifols eight-year commitment totaling 200 million IUs, the three-year agreement with CSL Behring for a total of 10 million IUs, and the agreement with Green Cross for 6 million IUs, there will now be a more predictable and sustainable flow of humanitarian aid donations to the global community. In addition, the initiatives of Project WISH and Project Recovery allow for the manufacturing of clotting factor concentrates from previously discarded cryopaste which provide treatment products to countries most in need.
Media Contact: Sarah Ford +1-514-266-7764 firstname.lastname@example.org
ATLANTA, April 11, 2017 (GLOBE NEWSWIRE) — Crawford & Company®, the world’s largest publicly listed independent provider of claims management solutions to insurance companies and self‐insured entities, today announced the appointment of Kieran Rigby as president of international, encompassing the United Kingdom, Europe, Asia-Pacific and Latin America regions.
Rigby was previously CEO of GAB Robins UK until Crawford acquired the company in 2014. Since then, Rigby served as CEO Crawford Europe and Latin America. In his new role, he assumes additional responsibility for the Asia-Pacific and United Kingdom regions, and he will serve as a member of Crawford’s Global Executive Management team (GEM).
“I’m confident Kieran is the right person for this role,” said Harsha V. Agadi, president and chief executive officer. “His character promotes both innovation and inspiration, and with his proven track record of leadership and success, I believe he’ll continue to grow our company and build for the future. I look forward to the new ideas and fresh focus he’ll bring to Crawford’s leadership team.”
Rigby, who will be based in London, will report directly to Andrew Robinson, global chief operating officer, and will be responsible for growing the business, continuing to strengthen Crawford’s global capabilities and realigning the company’s operating model for further efficiency and profitability across the company’s international businesses.
“Crawford’s global presence, strength and breadth of capabilities is unmatched by others in the marketplace,” Robinson said. “We are excited to have Kieran lead, grow and further develop our operations, as well as pursue new and innovative ways to serve our clients. I look forward to working with Kieran as we realize these ambitions.”
Rigby’s appointment follows the resignation of Ian V. Muress, CEO international, after 16 years of dedicated and loyal service to the company.
“We would like to thank Ian for the contribution he has made to the business and for his commitment to our clients,” said Agadi. “We wish him well as he moves to the next stage of his career.”
“It is a great honor to be given this opportunity,” said Rigby. “This is an exciting time for Crawford & Company. It is also a time to critically examine all parts of our operations to grow our revenue and presence in the marketplace – a marketplace that is rapidly changing and requiring our constant innovation.”
Throughout his career, Rigby has served in senior leadership positions in claims and loss adjusting, and he’s also active in the industry, holding excellent professional qualifications, including Fellow of the Chartered Insurance Institute, Chartered Insurance Practitioner, Fellow of Chartered Institute of Loss Adjusters and past president of the Federation of European Loss Adjusting Associations.
Based in Atlanta, Crawford & Company (NYSE:CRD‐A) (NYSE:CRD‐B) is the world’s largest publicly listed independent provider of claims management solutions to insurance companies and self‐insured entities with an expansive global network serving clients in more than 70 countries. The Crawford Solution® offers comprehensive, integrated claims services, business process outsourcing and consulting services for major product lines including property and casualty claims management, workers’ compensation claims and medical management, and legal settlement administration. More information is available at www.crawfordandcompany.com.
Media Contact: Nancy Hamlet 404.300.1918 email@example.com
April 9, 2017, Lt. Gen. Sansern Kaewkamnerd, Government Spokesperson, disclosed that the Government calls on all sectors that plan to celebrate Songkran Festival during April 13-17 to hold it under theme Enjoying traditional Songkran, Using water wisely, Ensuring everyone's safety, which campaigns for proper Songkran attires, water saving, and safe drives.
The real objective of Songkran is for everyone to preserve beautiful Thai tradition and identity, and express gratitude toward the elderlies and family members through water sprinkling. The public is urged to use small water guns or water bowls to splash water to each other instead of high-pressure equipment. They are also reminded to have their car checked and drive carefully during the holidays.
Prime Minister Gen. Prayut Chan-o-cha ordered all concerned agencies to facilitate and ensure public safety in all aspects. He wishes for everyone to enjoy their Songkran holidays.
According to the Government Spokesperson, Songkran highlight includes activities held at Thailand Cultural Center (April 11), Siam Paragon (April 13-16), and Siam Square (April 13-15) in Bangkok, as well as ASEAN celebration of Songkran in Loei province (Thai-Lao PDR cultural collaboration on April 10-16), Tak province (Thai-Myanmar Songkran celebration on April 13-16), and Chiang Rai province (Thai-Lao PDR Songkran celebration on April 12-17).
Source: Royal Thai Government
The deputy prime minister in charge of security said security authorities have been ordered to probe into a series of bombings and burning of electric supply power poles, telecommunication poles, and car tyres in the four southern provinces had any political link to the promulgation of the new constitution.
Gen Prawit Wongsuwan said he ordered the probe after several violent incidents happened simultaneously in Songkhla, Pattani, Yala and Narathiwat last night and early today.
But he admitted that security authorities have earlier warned of the attempted attacks during this period, and have placed all security on alert.
Gen Prawit said the government will still keep Section 44 in force as the country remains unstable.
He was commenting on call by political parties to relax the order and to allow them holding political activities after the new constitution is now in place.
Source: Thai Public Broadcasting Service (Thai PBS)